<DOC>
	<DOCNO>NCT02779608</DOCNO>
	<brief_summary>This clinical Study evaluate effect , survival benefit safety intraperitoneal docetaxel combine oral S-1 advance gastric cancer malignant ascites .</brief_summary>
	<brief_title>The Study Intraperitoneal Docetaxel Plus S-1 Malignant Ascites</brief_title>
	<detailed_description>Peritoneal metastasis ( PM ) common advanced gastric cancer associate poor prognosis . The median survival time 3 4 month even short patient malignant ascites . Systemic chemotherapy consider less effective peritoneal metastasis ( PM ) due existence blood-peritoneal barrier ( BPB ) , inhibits movement drug systemic circulation peritoneal cavity . S-1 one kind oral fluoropyrimidine derivative report effective PM . Docetaxel ( DTX ) pharmacokinetic advantage intraperitoneal（IP）delivery hundred time high systemic administration . The use S-1 docetaxel study phase II trial . Fujiwara Fushida report usefulness IP docetaxel combine oral S-1 regimen gastric cancer PM respectively，the median survival time exceed 16 month one year survival rate 70 % . Therefore , investigator suppose IP docetaxel oral S-1 also effective gastric cancer malignant ascites start study . This single center , open-label , prospective clinical trial . Patients histological proven gastric cancer ascites , fulfill inclusion exclusion criterion , recruit study . Patients firstly receive laparoscopic exploration Peritoneal Cancer Index ( PCI）score , extraction 100ml ascites cytology examination , one peritoneal access port implant subcutaneous space low abdomen . Then patient treat chemotherapy first day operation , regimen follow : DTX administer IP dose 60 mg/m2 day 1 . DTX dilute 1 litre normal saline administer implanted peritoneal access port 1 hour . S-1 administer orally twice daily dose 80 mg/m2 per day 14 consecutive day , follow 7 day rest . The treatment course repeat every three week observation disease progression unacceptable toxicity . Before intraperitoneal chemotherapy , investigator extract 50-100 ml ascites cytology pathologic examination , abdominal CT review every three course evaluate volume ascites . The volume ascites therapy , PCI score , ascites cytology result , complication , side effect condition survival state follow-up record analyzed evaluate effect , survival benefit safety study .</detailed_description>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>1 . Age 2075years 2 . Histologic confirmation gastric adenocarcinoma 3 . Positive peritoneal cytology histological proven PM 4 . Ascites CT scan 5 . Performance status ( PS ) ≤ 2 Eastern Cooperative Oncology Group ( ECOG ) scale 6 . Adequate bone marrow organ function define : Leucocyte≥3,000/ul Absolute neutrophil count ≥1,500/uL Platelet≥100,000/uL Total bilirubin≤1.5mg/dl ALT，AST≤ 2x ULN serum creatinine ≤1.5mg/dl 7 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 8 . Provision write informed consent 1 . Presence noncurable factor distant metastasis liver lung except peritoneum 2 . Other severe medical condition symptomatic infectious disease , active hemorrhage/bleeding , obstructive bowel disease 3 . Life expectation ≤ 3 month 4 . With malignant tumor 5. allergy therapeutic drug</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>malignant ascites</keyword>
</DOC>